A multicenter phase II study of brigatinib for patients with ALK fusion genes positive metastatic solid tumor - WJOG15221M/ XB99036

Toshiki Masuishi0 个研究点目标入组 28 人开始时间: 2022年2月18日最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•1) Voluntary written consent to participate in the study has been obtained
•2) Patients who are 20 years of age or older on the day informed consent is obtained
•3) Patients with a histologically confirmed diagnosis of advanced or recurrent solid tumor
•4) Patients with advanced or recurrent solid tumors that have become refractory or intolerant to standard therapies, or have no satisfactory standard therapy
•5) Patients with solid tumors positive for ALK-fusion genes
•6) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) guidelines version 1.1
•7) Patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
•8) Patients expected to survive for at least 3 months
•9) Patients who are able to receive oral administration
•10) Patients with adequate organ function as measured by the laboratory tests within 7 days prior to enrollment
•11) Patients of childbearing potential must have a negative urine pregnancy test within 14 days prior to enrollment
•12) Patients who consented to the use of adequate contraception from the time of signing informed consent to 4 months after the last dose of the investigational product

•1) Patients previously treated with ALK inhibitors
•2) Patients diagnosed with non-small cell lung cancer (NSCLC)
•3) Patients with symptomatic brain metastases or meningeal dissemination. However, asymptomatic brain metastases that do not require corticosteroid induction within 1 week of study enrollment or dose escalation can be considered eligible.
•4) Patients with meningeal dissemination
•5) Patients with clinically significant cardiac disease (requiring treatment)
•6) Patients with uncontrolled hypertension
•7) Patients with a history of interstitial lung disease or pulmonary fibrosis
•8) Patients with malabsorption syndrome or other gastrointestinal diseases that may affect drug absorption
•9) Patients who had undergone surgery with general anesthesia within 2 weeks prior to study enrollment
•10) Patients who had undergone treatment with chemotherapy, hormone therapy or radiotherapy within 2 weeks prior to study enrollment and monoclonal antibody (molecular-targeted therapy, antibody therapy, immunotherapy) within 4 weeks prior to study enrollment
•11) Synchronous or metachronous multiple cancers with a disease-free interval of <= 2 years at the time of enrollment
•12) Patients with known human immunodeficiency virus (HIV) infection
•13) Patients who are pregnant or breastfeeding
•14) Patients taking CYP3A inhibitors or CYP3A inducers within 14 days prior to enrollment
•15) Patients with other medically significant abnormalities

发起方

Toshiki Masuishi